Trinity Biotech Welcomes The Decision Of The High Court Of Kenya To Strike Out The Applications To Prevent the Procurement of TrinScreen HIV By The Kenyan Ministry of Health
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products, is celebrating a recent victory in the High Court of Kenya. The court has dismissed a lawsuit filed by Gamma Zenith Kenya Limited against Trinity Biotech, Radiance Pharmaceutical, the Kenyan Ministry of Health, and the Kenyan Attorney General. This lawsuit aimed to prevent the Kenyan Ministry of Health from procuring TrinScreen HIV test kits.
The High Court’s decision is a significant milestone for both public health in Kenya and Trinity Biotech. It signifies the removal of legal barriers that had previously hindered the sale of TrinScreen HIV test kits to the Kenyan Ministry of Health. With the court ruling in their favor, Trinity Biotech can now proceed with supplying TrinScreen HIV in Kenya.
Trinity Biotech is expecting to receive TrinScreen HIV orders for the new Kenyan HIV rapid testing algorithm very soon. This is a promising development, considering that the Kenyan HIV screening program is one of the largest in Africa, with an estimated annual number of screening tests reaching approximately 10 million.
In a separate legal case challenging the new HIV rapid testing algorithm, a ruling was scheduled for October 5, 2023. However, due to the unavailability of the trial judge, the ruling will be delivered at a later date. Trinity Biotech believes that there are currently no existing court orders prohibiting the Kenyan Ministry of Health from purchasing TrinScreen HIV test kits.
Trinity Biotech is a company dedicated to developing, acquiring, manufacturing, and marketing diagnostic systems for the point-of-care and clinical laboratory segments of the diagnostic market. Their products play a crucial role in detecting infectious diseases and measuring various chemistry parameters in serum, plasma, and whole blood, including Haemoglobin A1c levels.
With a direct presence in the United States, Germany, France, and the U.K., as well as a network of international distributors and strategic partners in over 75 countries worldwide, Trinity Biotech is well-positioned to make a positive impact on global healthcare.
This recent court victory in Kenya not only opens up new opportunities for Trinity Biotech but also underscores their commitment to advancing public health and providing innovative diagnostic solutions. As they continue to develop and deliver cutting-edge products, Trinity Biotech remains a key player in the fight against infectious diseases and the improvement of healthcare outcomes worldwide.
For more information about Trinity Biotech and their range of diagnostic products, please visit their website at www.trinitybiotech.com.